Colossal generates value not by selling resurrected animals but by spinning out valuable technology companies developed during its R&D, such as a computational biology platform. The long-term vision involves biodiversity credits rather than direct sales.

Because their platform generates more high-potential drug targets than they can pursue internally, the company frames partnerships with large pharmaceutical firms as an ethical imperative. This approach ensures novel findings don't languish, allowing them to become life-saving drugs while triggering revenue sharing for their community partners.

Anti-extinction startup Colossal is leveraging high-profile clients like Tom Brady for pet cloning. This creates buzz and revenue, effectively funding long-term R&D with a luxury consumer service while its more ambitious projects (reviving mammoths) are still in development.

Variant Bio's advantage lies in its ethical approach to partnering with indigenous communities. This model, which includes co-designing studies and robust benefit sharing, grants them exclusive access to unique genetic datasets that competitors, focused on traditional data sources, cannot obtain.

The 'AskNature' website catalogues nature's solutions to complex problems, providing a free R&D resource for product innovation. Entrepreneurs can leverage millions of years of evolution for design inspiration (e.g., water-resistant feathers) and create powerful, built-in marketing narratives for their products.

A Norwegian-backed project in the Congo Basin treats conservation like venture capital. It provides small grants (~$5k) to communities who pitch development ideas, like a pigsty or farm tools. In return for the seed funding, the community pledges to protect a portion of their forest from development, aligning financial prosperity with environmental protection.

Instead of fighting illegal loggers and gold miners, the Jungle Keepers organization hires them as salaried conservation rangers. This model provides a sustainable livelihood, turning the forest's primary destroyers into its most effective protectors and aligning economic incentives with environmental preservation.

The economic value of extending healthy life is astronomical. One research team estimated a single year of added healthspan is worth $38 trillion to the US economy, a figure experts believe is still an underestimate. This reframes geroscience investment as a massive economic opportunity, not a cost.

Thriving life sciences ecosystems in Ireland, the UK, and Massachusetts did not grow by accident. Their success is the result of deliberate, long-term government strategies, including tax incentives, shared R&D infrastructure like the UK's 'Catapult' network, and fostering deep connections between technology, hospitals, and capital.